.Pharmacolibrary.Drugs.ATC.A.A10BX02

Information

Repaglinide is an oral antihyperglycemic agent of the meglitinide class used to manage type 2 diabetes mellitus by stimulating insulin secretion from the pancreas. It is approved and widely used today for glycemic control in adults with type 2 diabetes.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult volunteers, single-dose administration, both sexes, age 18-60.

References

1. Ruzilawati, AB, & Gan, SH (2010). CYP3A4 genetic polymorphism influences repaglinide's pharmacokinetics. Pharmacology 85(6) 357–364. DOI:10.1159/000302731 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20523106

2. Kirchheiner, J, et al., & Brockmöller, J (2005). Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clinical pharmacokinetics 44(12) 1209–1225. DOI:10.2165/00003088-200544120-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16372821

3. He, J, et al., & Chen, X (2011). Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers. European journal of clinical pharmacology 67(7) 701–707. DOI:10.1007/s00228-011-0994-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21327909

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)